On February 6, Tonghua Dongbao announced that Dongbao Zixing (Hangzhou) Biopharmaceutical, a wholly-owned subsidiary of the company, recently obtained the notice of acceptance of the clinical trial application for the indication of THDBH120 for weight loss for injection issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. On the same day, Hengrui Pharmaceutical announced that its subsidiary obtained the notice of approval for the clinical trial of HRS-7535 tablets, and agreed to carry out phase clinical trials of this product for weight loss indications.
Novo Nordisk, the majority shareholder of Novo Nordisk, announced that Novo Nordisk will acquire Catalent's three bottling plants in Anani, Italy, Brussels, Belgium and Bloomington, Indiana, USA from Novo Holding for an upfront payment of US$11 billion. The company said the new facility will serve more people with diabetes and obesity, and the acquisition will help expand production scale and speed. Founder ** pointed out that GLP-1 drugs are developing rapidly, moving towards multi-target and oral. At present, the research and development of GLP-1 drugs is hot, with more than 100 new drugs related to GLP-1 under development worldwide, and dozens of GLP-1 drugs developed by Chinese pharmaceutical companies are also under development. With the increase in the number of obese people and the enhancement of residents' awareness of weight management, the potential development space of the first-class drug market is broad.
According to the theme database of the Financial Associated Press, among the relevant listed companies:
Hanyu PharmaceuticalsSigned a major contract with overseas customers for daily operations, according to the contract, the customer is expected to purchase a total of 30 million US dollars of GLP-1 peptide APIs from the company and Hanyu Wuhan.
Livzon GroupIn the survey, it was said that the process route adopted by the company's semaglutide is biological fermentation method, non-chemical synthesis. The holding subsidiary of New Beijiang Pharmaceutical's semaglutide injection for weight loss indication was approved for clinical trial.
Finance Associated Press).